Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

This phase 1, multi‐center, nonrandomized, open‐label, dose‐escalation study consisted of Part A wherein merestinib 80 or 120 mg (40‐mg tablets) was administered orally QD during a 28‐day cycle to patients diagnosed with solid tumors and Part B wherein merestinib 80 mg (40‐mg tablets) was administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Yamamoto, Noboru, Naito, Yoichi, Kuboki, Yasutoshi, Koyama, Takafumi, Piao, Yongzhe, Tsujimoto, Naoto, Asou, Hiroya, Inoue, Koichi, Kondo, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495281/
https://www.ncbi.nlm.nih.gov/pubmed/34499416
http://dx.doi.org/10.1002/cam4.4110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495281/
https://www.ncbi.nlm.nih.gov/pubmed/34499416
http://dx.doi.org/10.1002/cam4.4110

Ejemplares similares